Hartford Investment Management Co. reduced its position in West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating ) by 7.1% during the first quarter, HoldingsChannel reports. The firm owned 6,984 shares of the medical instruments supplier’s stock after selling 535 shares during the period. Hartford Investment Management Co.’s holdings. in West Pharmaceutical Services were worth $2,868,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Modera Wealth Management LLC acquired a new position in West Pharmaceutical Services during the 4th quarter valued at approximately $285,000. ARK Investment Management LLC purchased a new stake in West Pharmaceutical Services during the 1st quarter valued at approximately $179,000. Robeco Institutional Asset Management BV raised its position in West Pharmaceutical Services by 10.6% in the 4th quarter. Robeco Institutional Asset Management BV now owns 167,783 shares of the medical instruments supplier’s stock valued at $78,693,000 after purchasing an additional 16,138 shares in the last quarter. Mirabella Financial Services LLP boosted its holdings in shares of West Pharmaceutical Services by 70.3% during the 4th quarter. Mirabella Financial Services LLP now owns 21,864 shares of the medical instruments supplier’s stock valued at $10,254,000 after purchasing an additional 9,024 shares in the last quarter. Finally, Endowment Wealth Management Inc. purchased a new position in shares of West Pharmaceutical Services in the 4th quarter valued at $7,305,000. 93.25% of the shares are owned by hedge funds and other institutional investors.
Separately, StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th.
Shares of West Pharmaceutical Services stock opened at $307.74 on Friday. West Pharmaceutical Services, Inc. has a twelve month low of $275.89 and a twelve month high of $475.35. The firm has a market cap of $22.80 billion, a P/E ratio of 34.19, a price-to-earnings-growth ratio of 3.10 and a beta of 1.18. The firm’s 50-day simple moving average is $304.53, and its 200-day simple moving average is $366.39. The company has a debt-to-equity ratio of 0.09, a quick earnings ratio of 2.18 and a current ratio of 2.89.
West Pharmaceutical Services (NYSE:WST – Get Rating ) last announced its earnings results on Thursday, April 28th. The medical instruments supplier reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.18 by $0.12. West Pharmaceutical Services had a net margin of 23.76% and a return on equity of 30.33%. The company had revenue of $720.00 million during the quarter, compared to the consensus estimate of $720.92 million. During the same period in the previous year, the firm reported $2.05 earnings per share. The company’s revenue increased by 7.4% year-on-year. Equities analysts predict that West Pharmaceutical Services, Inc. will report 9.33 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 3rd. Investors of record on Wednesday, July 20th will be paid a dividend of $0.18 per share. This represents an annual dividend of $0.72 and a yield of 0.23%. The ex-dividend date is Tuesday, July 19th. West Pharmaceutical Services’s dividend payout ratio is currently 8.00%.
West Pharmaceutical Services Profile (Get Rating)
West Pharmaceutical Services, Inc designs, manufactures and sells systems for the containment and delivery of injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa and the Asia Pacific region. It operates in two segments, own products and contract manufactured products.
Want to see what other hedge funds hold WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating ).
Get West Pharmaceutical Services news and ratings daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for West Pharmaceutical Services and related companies with MarketBeat.com ‘s FREE daily email newsletter.